Compare ProShares Ultra QQQ ETF (QLD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Twist Bioscience Corp — how do they compare? ProShares Ultra QQQ ETF trades at $97.85 (market cap $15.38B), while Twist Bioscience Corp trades at $160.37 (market cap $10.08B). The key difference: ProShares Ultra QQQ ETF is the larger of the two by market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 37 Days and Twist Bioscience Corp for 27 Days on average.
| QLD | TWST | |
|---|---|---|
Market Cap | $15.38B | $10.08B |
Volume | 4,844,085 | 4,229,037 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $205.00 |
52-Week Low | $57.16 | $25.45 |
Typical Hold Time | 37 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD trades at $100.23, down 0.54% on the day, with technical indicators showing a bullish moving average signal but overbought RSI conditions. The ETF maintains support at $99 and resistance at $101, with institutional buying activity noted in recent filings. Recent news highlights QLD's resilience compared to more leveraged alternatives during market downturns.
The outlook remains cautiously optimistic given strong technical momentum, though overbought conditions suggest potential near-term consolidation. Key risks include Federal Reserve policy impacts and Nasdaq volatility, while institutional accumulation supports medium-term bullish sentiment.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
